Phase 2 N=52 Pilot Trial of Chlorhexidine Gluconate (CHG) Preoperative Skin Preparation
Surgery
Primary: Log Change in Bacterial Flora on Abdomen and Groin — 2.9; 3.7; 2.3; 3.0 Log (CFU)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=390 Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved American College of Rheumatology 20 Percent (%) Response Criteria (ACR20) Assessed Using High-Sensitivity C-reactive Protein…
Phase 2 N=12 Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency
Tetrahydrobiopterin Deficiencies · Hyperphenylalaninemia, Non-Phenylketonuric
Primary: Blood Phenylalanine(Phe) Levels Measured at Specified Timepoints — 132.9; 72.2; 315.0; 104.1 μmol/L
Phase 2 N=91 Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Relapsed or Refractory Chronic Lymphocytic Leukemia · Relapsed or Refractory Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) — 80 Participants — p=<0.0001
Phase 2 N=111 A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage
Phase 2 N=227 A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
Diabetic Macular Edema
Primary: Mean Change From Baseline in BCVA Letter Score at Week 24, in Treatment-Naive Participants — 10.3; 11.7; 13.9 BCVA letters — p=0.37
Phase 2 N=188 Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
Malaria
Primary: Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) — 11.1; 0; 0; 0…
Phase 2 N=75 Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)
PTSD
Primary: Clinician Administered PTSD Scale (CAPS) Score — -21.1; -16.7 score on a scale — p=0.442
Phase 2 N=81 Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
Recurrent Glioblastoma
Primary: Progression-Free Survival at 6 Months (PFS-6) — 31; 15 percentage of participants
Phase 2 N=88 Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Choroidal Neovascularization · Age-related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Month 3 — .3; 6.8; 7.6 Letters
Phase 2 N=23 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Constrictive Bronchiolitis · Bronchiolitis Obliterans · Graft vs Host Disease
Primary: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) — 9; 0 Participants
Phase 2 N=95 Dose Ranging Study of OTO-201 in AOMT
Acute Otitis Media · AOMT
Primary: Number of Subjects With Adverse Events — 19; 14; 4 Participants
Phase 2 N=6 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
Eosinophilic Esophagitis · Connective Tissue Disorders
Primary: Percent of Participants in Histologic Remission at 16 Weeks — 17; 17 percentage of participants
Phase 2 N=120 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndromes · Leukemia, Myelomonocytic, Chronic · Leukemia, Myeloid, Acute
Primary: Overall Survival (OS) — 19.0; 21.8 months — p=0.464
Phase 2 N=36 Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 4.3 months